Endocrine Abstracts

Background: Up to 60% of patients with neuroendocrine tumours (NETs) are malnourished. This negatively impacts survival, length of hospital stay, risk of complications, treatment response, fatigue and quality of life. Malnutrition is typically defined by body mass index (BMI) or weight loss, which provides no information on body composition. Research in other cancers has shown sarcopenia is more significant than BMI. Information is lacking on the influence of ...

Introduction/Background: Somatostatin analogue injections are a mainstay for the treatment of Neuroendocrine Tumours. Gallstones are a known adverse effect of this treatment. PRRT can bring extra complications for patients having an episode of cholecystitis, biliary colic, cholangitis or pancreatitis.Aims: To examine a cohort of patients undergoing PRRT, looking for the incidence of gallstones and how many patients suffe...

Introduction/Background: PRRT is a high cost treatment for progressing Neuroendocrine tumours. Patients and healthcare providers invest heavily in the treatment journey that lasts a number of months.Aims: To assess the level of patient satisfaction with the PRRT service, to indicate areas for possible improvement and good practice and serve as a baseline for future assessments.Material and ...

Introduction/Background: Neuroendocrine Tumour (NET) patients can have specialist and complex needs and this can be exacerbated when they have PRRT. A new role was envisaged that would utilise a NET Clinical Nurse Specialist to work with both Nuclear Medicine and the NET team for delivering PRRT.Aims: As part of the wider NET team the aim for the new CNS was to embed outpatient PRRT delivery, increase capacity and delive...